/

Società

Ko

Non verificato

Kowa Company Ltd.

Di cosa scriviamo

Ecologia/Salute ambientaleFarmaceuticaFitnessMedicina - VarieSalute

3 comunicati stampa

Guarda tutti i comunicati

Press Release cover image

30/06/2026

Salute

Fitness

Medicina - Varie

Ecologia/Salute ambientale

Agricoltura

Selective PPARα Modulator "K-808" (Pemafibrate) Granted "Breakthrough Therapy" Designation by the U.S. Food and Drug Administration (FDA) As a Treatment for Primary Biliary Cholangitis

Fonte

Kowa Company Ltd.

Emittente

1.00

0

Press Release cover image

06/04/2026

Salute

Fitness

Medicina - Varie

K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate Demonstrates Tumor-Selective Pharmacokinetics, Extensive Intratumoral Distribution and Superior Efficacy in Non-Clinical Animal Models

Fonte

Kowa Company Ltd.

Emittente

1.00

0

21/04/2025

Farmaceutica

Sanità

Finanza

K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate with Ultra-High Drug Loading Capacity Demonstrates Superior Efficacy in EGFR-Expressing Solid Tumors

Fonte

Kowa Company Ltd.

Emittente

1.00

0

Seguaci

0

Compatibilità

0